পদ্ধতির তুলনা করুন
নির্বাচিত পদ্ধতিগুলো পাশাপাশি পর্যালোচনা করুন; যে সারিগুলোয় পার্থক্য আছে সেগুলো চিহ্নিত করা হয়।
| এএলএস ফাংশনাল রেটিং স্কেল রিভাইজড (ALSFRS-R)× | মাল্টিপল স্ক্লেরোসিস ওয়াকিং স্কেল-১২ (MSWS-12)× | |
|---|---|---|
| ক্ষেত্র | স্নায়ুবিজ্ঞান | স্নায়ুবিজ্ঞান |
| পরিবার | Process / pipeline | Process / pipeline |
| উদ্ভবের বছর≠ | 1999 | 2003 |
| প্রবর্তক≠ | James M. Cedarbaum, NIH/NINDS | Jeremy C. Hobart, University of Plymouth |
| ধরন≠ | Clinician-rated and patient-reported hybrid | Self-report questionnaire |
| মৌলিক উৎস≠ | Cedarbaum, J. M., Stambler, N., Malta, E., Fuller, C., Hilt, D., Thurmond, B., & Nakanishi, A. (1999). The ALSFRS-R: A revised ALS functional rating scale that incorporates assessments of respiratory function. Journal of the Neurological Sciences, 169(1-2), 13-21. DOI ↗ | Hobart, J. C., Riazi, A., Lamping, D. L., Fitzpatrick, R., & Thompson, A. J. (2003). Measuring the impact of MS on walking ability: The 12-Item MS Walking Scale (MSWS-12). Neurology, 60(1), 31-36. DOI ↗ |
| অপর নাম | ALS FRS-R, Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised | MS Walking Scale-12, MSWS |
| সম্পর্কিত≠ | 4 | 3 |
| সারসংক্ষেপ≠ | The ALSFRS-R is a 12-item clinician-administered functional rating scale designed to assess disease progression and functional status in amyotrophic lateral sclerosis (ALS). Introduced by Cedarbaum and colleagues in 1999, it expands upon the original ALSFRS by incorporating respiratory function assessment. It is the primary outcome measure in ALS clinical trials and routine clinical monitoring, providing quantitative tracking of disease decline that predicts survival and guides management decisions. | The MSWS-12 is a brief, patient-reported outcome measure specifically designed to assess the impact of multiple sclerosis on walking ability and limitation. Developed by Hobart and colleagues in 2003, this 12-item scale captures both the physical difficulty and functional consequences of MS-related gait impairment. It is highly responsive to change and widely used in MS clinical trials and practice as a primary outcome measure for assessing intervention effects on mobility. |
| ScholarGateডেটাসেট ↗ |
|
|